$14.42
8.62% today
Nasdaq, Apr 04, 08:49 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$15.78
-2.66 14.43% 1M
-13.50 46.11% 6M
-8.99 36.29% YTD
-15.40 49.39% 1Y
+10.13 179.29% 3Y
+1.58 11.13% 5Y
+5.83 58.59% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.64 3.90%
ISIN
US45258J1025
Symbol
IMVT
Sector

Key metrics

Market capitalization $2.68b
Enterprise Value $2.31b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 6.59
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-405.21m
Free Cash Flow (TTM) Free Cash Flow $-325.64m
Cash position $374.69m
EPS (TTM) EPS $-2.62
P/E forward negative
Short interest 18.06%
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Immunovant Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Immunovant Inc forecast:

Buy
86%
Hold
14%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.33 0.33
70% 70%
-
-0.33 -0.33
70% 70%
-
- Selling and Administrative Expenses 71 71
35% 35%
-
- Research and Development Expense 333 333
66% 66%
-
-405 -405
59% 59%
-
- Depreciation and Amortization 0.33 0.33
70% 70%
-
EBIT (Operating Income) EBIT -405 -405
58% 58%
-
Net Profit -383 -383
57% 57%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Positive
Seeking Alpha
16 days ago
Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoclimab in phase 2b study targeting patients with Chronic Inflammatory Demyelinating Polyneuropathy; IgG was reduced by ≥ 70%. Data from both phase 3 studies, using batoclimab to treat patients with ...
Neutral
PRNewsWire
16 days ago
NEW YORK , March 19, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant's directors breached their fiduciary duties in connection with recent corporate actions.
Positive
Investors Business Daily
16 days ago
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Peter Salzmann
Employees 207
Founded 2018
Website www.immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today